[ad_1]
New York, March 16, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Anemia And Other Blood Disorder Drugs Global Market Report 2022” – https://www.reportlinker.com/p06245020/?utm_source=GNW
Novartis AG and Janssen Pharmaceutical.
The global anemia and other blood disorder drugs market is expected to grow from $10.29 billion in 2021 to $11.10 billion in 2022 at a compound annual growth rate (CAGR) of 7.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $14.32 billion in 2026 at a CAGR of 6.6%.
The anemia and other blood disorder drugs market consists of sales of anemia and other blood disorder drugs and related services. Anemia and other blood disorder drugs that are used to stimulate red blood cell production or hemoglobin in the human body include Erythropoietin (Epoetin alpha), Ferrous Sulfate, Iron Dextran, Deferoxamine, Immunosuppressant, Bone marrow stimulants, Corticosteroids, Aminoxin, Hespan, Hextend, and Pyridoxine.
The market also comprises sales of drugs that are responsible for curing other blood disorders, including inherited orphan blood disorder.
The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia and aplastic anemia. Iron deficiency anaemia is a common kind of anaemia in which the blood does not contain enough healthy red blood cells.
The oxygen-carrying red blood cells transport oxygen to the body’s cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), macrocytic (High MCV) and …
Full story available on Benzinga.com
[ad_2]
Source link
